Shareholders vote in favor of all proposals by the Board at Idorsia's Annual General Meeting 2025
Allschwil, Switzerland – May 28, 2025
At today's Annual General Meeting (AGM) of Idorsia Ltd (SIX: IDIA) held in Basel, Switzerland, shareholders voted convincingly in favor of all proposals by the Board of Directors.
The meeting was attended by 166 shareholders, representing a total of 97'748'740 shares, or 43.28% of the total outstanding shares.
Led by the Chairman of the Board, Jean-Paul Clozel the company presented a business update.
Jean-Paul Clozel, MD, Chairman of the Board of Directors, commented:
'On behalf of the Board, I would like to thank the shareholders for their support and loyalty. I strongly believe that with their backing, with our products and pipeline, and with our people working to ramp-up the sales of QUVIVIQ and activate the pipeline, Idorsia can become one of the most successful biotech companies in Europe.'
The shareholders approved the Annual Report 2024, the Consolidated Financial Statements 2024, and the Statutory Financial Statements 2024. Shareholders also endorsed the Compensation Report 2024 and the Sustainability Report 2024 by way of consultative vote.
The shareholders approved the appropriation of available earnings and that the net loss for the year 2024 be carried forward.
The shareholders granted discharge to all members of the Board of Directors and of the Executive Committee for the financial year 2024.
The shareholders approved the amendments to the Articles of Association regarding share capital.
The shareholders re-elected all Board members who stood for re-election for a term of office until the conclusion of the AGM 2026. In addition, the shareholders elected Jean-Paul Clozel as Chairman of the Board, and the members of the Nominating, Governance and Compensation Committee: Srishti Gupta, Mathieu Simon, and Bart Filius. Following the AGM, the Board of Directors of Idorsia comprises a total of 5 members: Jean-Paul Clozel (Chairman), Mathieu Simon, Srishti Gupta, Sandy Mahatme, and Bart Filius.
Shareholders approved the aggregate maximum amount of compensation for the Board of Directors for the term of office until the AGM 2026 and aggregate maximum amount of compensation for the Idorsia Executive Committee (IEC) for the financial year 2026.
BachmannPartner AG, who was represented by Mr Alain Bachmann, was re-elected as Independent Proxy for a term of office until the conclusion of the AGM 2026.
Deloitte AG, Basel, was re-elected as the company's statutory auditors for the financial year 2025 (for a term of office until the conclusion of the AGM 2026).
Notes to the editor
About Idorsia
Idorsia Ltd is reaching out for more – we have more passion for science, we see more opportunities, and we want to help more patients.
The purpose of Idorsia is to challenge accepted medical paradigms, answering the questions that matter most. To achieve this, we will discover, develop, and commercialize transformative medicines – either with in-house capabilities or together with partners – and evolve Idorsia into a leading biopharmaceutical company, with a strong scientific core.
Headquartered near Basel, Switzerland – a European biotech hub – Idorsia has a highly experienced team of dedicated professionals, covering all disciplines from bench to bedside; QUVIVIQ™ (daridorexant), a different kind of insomnia treatment with the potential to revolutionize this mounting public health concern; strong partners to maximize the value of our portfolio; a promising in-house development pipeline; and a specialized drug discovery engine focused on small-molecule drugs that can change the treatment paradigm for many patients.
Idorsia is listed on the SIX Swiss Exchange (ticker symbol: IDIA).
For further information, please contactInvestor & Media RelationsIdorsia Pharmaceuticals Ltd, Hegenheimermattweg 91, CH-4123 Allschwil+41 58 844 10 10
[email protected] – [email protected] – www.idorsia.com
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
5 hours ago
- Yahoo
Lyell Immunopharma Strengthens Clinical and Commercial Capabilities with Key Board and Executive Appointments
Mark J. Bachleda, PharmD, MBA appointed as independent member of the Board of Directors David Shook, MD appointed as Chief Medical Officer, Mark Meltz, JD as General Counsel and Corporate Secretary, and Jarrad Aguirre, MD, MBA as Senior Vice-President of Medical Affairs SOUTH SAN FRANCISCO, Calif., June 09, 2025 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with cancer, today announced the appointment of Mark J. Bachleda, PharmD, MBA as an independent member of the Board of Directors, David Shook, MD as Chief Medical Officer, and Mark Meltz, JD as General Counsel and Corporate Secretary. These appointments, along with the appointment earlier in the year of Jarrad Aguirre, MD, MBA as Senior Vice President, Medical Affairs, further strengthen the Company's clinical and commercial capabilities. 'As Lyell prepares to move forward with two pivotal programs designed to advance LYL314 towards approval for patients with aggressive large B-cell lymphoma, we are delighted to welcome leaders who further strengthen and bring new expertise to our Board of Directors and our Executive Committee,' said Lynn Seely, MD, Lyell's President and Chief Executive Officer. 'Collectively, these new leaders have deep cell therapy expertise and highly relevant experience launching new medicines for patients. We look forward to their contributions as we continue to make progress on achieving our mission of bringing next-generation cell therapies to patients with cancer.' 'The addition of Dr. Bachleda to the Lyell Board provides us with experienced commercial leadership, including in cell therapy, at this critical time as Lyell becomes a late-stage clinical company initiating pivotal clinical trials and anticipating a commercial launch of LYL314,' said Rick Klausner, MD, Chairman of the Lyell Board of Directors. 'I could not be more pleased with the progress the company is making and am confident that our new executive leaders will ensure operational excellence as we focus on rapidly advancing LYL314, our autologous CD19/CD20 CAR T-cell therapy, to patients.' Mark J. Bachleda, PharmD, MBA appointed independent member of the Board of Directors Dr. Bachleda is currently the Chief Executive Officer and a member of the Board of Directors of Eyconis, Inc., a biopharmaceutical company focused on developing therapeutics for eye diseases. He has served in executive leadership roles at Amgen, Juno Therapeutics, and Bristol Myers Squibb (BMS), and, most recently, he was Chief Commercial Officer at Galera Therapeutics. Prior to joining Galera, he served as Vice President & U.S. Business Unit Head of the CAR T-cell therapy franchise at BMS, a role he held previously at Celgene Corporation before its acquisition by BMS. Prior to this, he was Vice President, Sales & Account Management at Juno when it was acquired by Celgene. His experience includes a 15-year career at Amgen in the U.S. and international roles of increasing responsibility up to Country President & General Manager of Amgen Czech Republic. Earlier in his career, he held positions at Pfizer, Inc., and Johnson & Johnson. Dr. Bachleda is a registered pharmacist and received his PharmD degree from the University of Illinois at Chicago. He completed a post-doctoral fellowship in health policy and economics at Thomas Jefferson University and earned MBA degrees from both Columbia University and the University of California, Berkeley. David Shook, MD appointed Chief Medical Officer Dr. Shook is an early pioneer of cell therapy and remains a practicing pediatric oncologist and transplant physician. Prior to Lyell, Dr. Shook was Chief Medical Officer and Head of Research and Development at Nkarta where he was responsible for leading the clinical development of multiple CAR NK cell product candidates for oncology. Prior to joining Nkarta, Dr. Shook held roles as Medical Director, Pediatric Cellular Therapy at AdventHealth and was Fellowship Director and a Faculty Member at St. Jude Children's Research Hospital. While at St. Jude, he conducted multiple first-in-human cell therapy trials, as well as research in the laboratory of Dario Campana, MD, PhD where he co-developed the membrane bound form of interleukin-15. He earned an MD from The Johns Hopkins University School of Medicine and a BS from Purdue University. Mark Meltz, JD appointed General Counsel and Corporate Secretary Mr. Meltz is an accomplished legal and business executive with more than two decades of experience leading and advising life sciences, technology and emerging growth companies. Prior to joining Lyell, Mr. Meltz was Chief Operating Officer and General Counsel of Kinnate Biopharma Inc., a clinical stage precision oncology company, through its sale to XOMA Corporation. Before Kinnate, he was Senior Vice President and General Counsel of Audentes Therapeutics through its sale to Astellas Pharma. Mr. Meltz also was previously Executive Vice President and Chief Business Development and Legal Officer at PaxVax through its sale to Emergent BioSolutions. Earlier in his career, Mr. Meltz was Associate General Counsel at Biogen and Head of Legal for North America at Novartis in its Vaccines & Diagnostics division. Mr. Meltz has supported multiple commercial launches at PaxVax, Biogen and Novartis. He earned a BA with Departmental Honors in Psychology from Yale University and a JD, Magna Cum Laude, from Boston College Law School. Jarrad Aguirre, MD, MBA appointed Senior Vice President, Medical Affairs Dr. Aguirre joined Lyell as Senior Vice President, Medical Affairs in January 2025. Prior to Lyell, Dr. Aguirre was Co-Founder and Chief Executive Officer of Miga Health, a digital health company focused on heart health, through its sale to Bitterroot Bio. Before Miga Health, Dr. Aguirre served in leadership roles at Myovant Sciences, most recently as Head of Corporate Strategy. Dr. Aguirre earned an MD and an MBA from Stanford University, an MPhil in Medical Anthropology from the University of Oxford as a Rhodes Scholar, and a BS in Biology from Yale University. About Lyell Immunopharma, Inc. Lyell is a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with hematologic malignancies and solid tumors. To realize the potential of cell therapy for cancer, Lyell utilizes a suite of technologies to endow CAR T cells with attributes needed to drive durable tumor cytotoxicity and achieve consistent and long-lasting clinical responses, including the ability to resist exhaustion, maintain qualities of durable stemness and function in the hostile tumor microenvironment. To learn more, please visit Forward-Looking Statements This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements expressed or implied in this press release include, but are not limited to, statements regarding: the performance of the Company's additions to its leadership team and Board of Directors, including the anticipated benefits of expanded strength of the Company's clinical and commercial capabilities; the continued clinical progress and anticipated commercial launch of the LYL314 trials; Lyell's anticipated progress, business plans, business strategy and clinical trials; Lyell's advancement of its pipeline, technology platform and research, development and clinical capabilities; the potential clinical benefits and therapeutic potential of Lyell's product candidates; and other statements that are not historical fact. These statements are based on Lyell's current plans, objectives, estimates, expectations and intentions, are not guarantees of future performance and inherently involve significant risks and uncertainties. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of these risks and uncertainties, which include, but are not limited to, risks and uncertainties related to: the ability to retain the continued service of its key personnel; the complexity of manufacturing cellular therapies, which subjects Lyell to a multitude of manufacturing risks, any of which could substantially increase our costs, delay Lyell's programs or limit supply of Lyell's product candidates; the effects of macroeconomic conditions, including the effects of disruption between the U.S. and its trading partners due to tariffs or other policies, any geopolitical instability and actual or perceived changes in interest rates and economic inflation; Lyell's ability to initiate or progress clinical trials on the anticipated timelines, if at all; Lyell's limited experience as a company in enrolling and conducting clinical trials, and lack of experience in completing clinical trials; the nonclinical profiles of Lyell's product candidates or technology not translating in clinical trials; the potential for results from clinical trials to differ from nonclinical, early clinical, preliminary or expected results; significant adverse events, toxicities or other undesirable side effects associated with Lyell's product candidates; the significant uncertainty associated with Lyell's product candidates ever receiving any regulatory approvals; Lyell's ability to obtain, maintain or protect intellectual property rights related to its product candidates; implementation of Lyell's strategic plans for its business and product candidates; the sufficiency of Lyell's capital resources and need for additional capital to achieve its goals; and other risks, including those described under the heading 'Risk Factors' in Lyell's Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, filed with the Securities and Exchange Commission on May 13, 2025. Forward-looking statements contained in this press release are made as of this date, and Lyell undertakes no duty to update such information except as required under applicable law. Contact: Ellen RoseSenior Vice President, Communications and Investor Relationserose@ in to access your portfolio
Yahoo
6 hours ago
- Yahoo
Oasis Intends to Vote Against Kyocera's Top Management at the Upcoming AGM
*Kyocera has been facing chronic underperformance, with its stock price remaining depressed over the long-term and profitability continuing to deteriorate sharply *Although Kyocera has announced certain management reform initiatives, they fall far short of the necessary fundamental changes needed to transform the Company *On May 14, Oasis released a "Seven-Point Plan" calling for more substantive reforms at Kyocera, including the acceleration of non-core business divestitures and improvements to the Company's inefficient capital structure *However, Kyocera has so far failed to address the "Seven Point Plan" and has demonstrated little commitment to genuine transformation *In its latest results, Kyocera achieved an ROE of just 0.8% *Oasis will vote against the reappointment of Chairman Yamaguchi and President Tanimoto at the upcoming AGM, holding them accountable for the underperformance and poor capital allocation *Both ISS and Glass Lewis have recommended to vote against the reappointment of Kyocera Chairman Yamaguchi, and ISS additionally recommends voting against President Tanimoto More information available at HONG KONG, June 11, 2025--(BUSINESS WIRE)--Oasis Management Company Ltd. ("Oasis") is manager to funds that beneficially own shares in Kyocera Corporation (6971 JP) ("Kyocera" or the "Company"). Oasis has adopted the Japan FSA's "Principles of Responsible Institutional Investors" (a.k.a. the Japan Stewardship Code) and in line with those principles, Oasis monitors and engages with its investee companies. At its May 14, 2025 earnings call, Kyocera reported on the progress of its management reforms. The Company appeared to acknowledge its past mistakes and expressed an intention to take the first step toward change. Specifically, Kyocera recognized the inefficiencies caused by the dispersal of management resources due to diversification and announced its policy to restructure its business portfolio in order to focus on its core strengths. However, like many shareholders and market participants, Oasis remains highly skeptical of Kyocera's commitment and ability to execute meaningful change especially in light of its modest plans and continued commitment to manufacturing solar panels and telecommunication devices. Moreover, underperformance against its management targets has become the norm. Since the fiscal year ended March 2020, Kyocera has exceeded its operating profit targets only once. This track record raises serious concerns about the current management team's ability to formulate and execute plans, casting significant doubt on whether they can even implement the current, modest reform plan. The latest earnings briefing further highlighted weak progress. Although Kyocera announced plans to exit JPY200 billion worth of non-core businesses, only JPY7.3 billion has been announced so far. This year's forecast includes just a JPY10 billion revenue reduction from exits. Kyocera's capital policy also remains insufficient. Although the Company has announced "Future Reduction Plan" to lower cross-shareholdings to below 20% of net assets, it has yet to provide a clear timeline for achieving this goal. Shareholders' dissatisfaction is growing. Approval for the Company's president at the AGM has dropped from 96% in 2015 to just 65% in 2023. ISS and Glass Lewis have once again recommended voting against the reappointment of Kyocera's Chairman, Mr. Yamaguchi. ISS has also recommended voting against President, Mr. Tanimoto, citing continued underperformance in ROE and capital misallocation. Oasis also believes that the top management is responsible for Kyocera's weak performance and therefore intends to vote against the reappointment of both individuals. Amid growing pressure from shareholders, Kyocera announced plans to reduce the cap on board directors from 20 to 12. At the same time, the Company also plans to increase the number of internal directors -- a move that runs against the broader efforts by many Japanese companies to strengthen board independence thereby decreasing the percentage of independent directors. In order for Kyocera to achieve genuine transformation and resolve its excessive diversification and inefficient capital structure, Oasis urges the full implementation of the following Seven-Point Plan: Divest non-core businesses amounting to over JPY660 billion of revenue. Exit the Organic Packages to prevent further losses. Restructure its KAVX subsidiary to achieve higher margins in line with peers. Stop losses by halting investment into GaN and millimeter-wave technologies which have little potential to produce material returns. Focus on its core business such as ceramics to capture untapped opportunities. Commit to aggressive M&A to reinforce core businesses. Announce a buyback program of JPY1 trillion over the next four years, amounting to approximately 37% of the Company. By implementing this plan, we believe that the stock could see an upside of over +100% from current levels. Seth Fischer, Founder & Chief Investment Officer of Oasis, said: "Kyocera's excessive diversification has long prevented it from realizing its full potential. The Company continues to support underperforming businesses while failing to prioritize investment and growth opportunities within its best businesses such as ceramics packaging, and the automotive and semiconductor sectors. With cross-shareholdings still accounting for 53% of its net assets and an ROE of just 0.8%, the time for meaningful change is now. Management needs to address the twin problems of over-diversification and over-capitalization of its balance sheet by exiting underperforming businesses, leaning into its best growth opportunities, and taking a much more ambitious stance on unwinding cross-shareholdings to improve returns on capital. Kyocera needs brave, large steps forward to achieve these goals. The current half measures are not enough." Full details can be viewed at All stakeholders are encouraged to contact Oasis at info@ *** Oasis Management Company Ltd. manages private investment funds focused on opportunities in a wide array of asset classes across countries and sectors. Oasis was founded in 2002 by Seth H. Fischer, who leads the firm as its Chief Investment Officer. More information about Oasis is available at Oasis has adopted the Japan FSA's "Principles for Responsible Institutional Investors" (a.k.a. the Japan Stewardship Code) and, in line with those principles, Oasis monitors and engages with our investee companies. The information and opinions contained in this press release (referred to as the "Document") are provided by Oasis Management Company ("Oasis") for informational or reference purposes only. The Document is not intended to solicit or seek shareholders to, jointly with Oasis, acquire or transfer, or exercise any voting rights or other shareholder's rights with respect to any shares or other securities of a specific company which are subject to the disclosure requirements under the large shareholding disclosure rules under the Financial Instrument and Exchange Act. Shareholders that have an agreement to jointly exercise their voting rights are regarded as Joint Holders under the Japanese large shareholding disclosure rules and they must file notification of their aggregate shareholding with the relevant Japanese authority for public disclosure under the Financial Instruments and Exchange Act. Except in the event that Oasis expressly enters into the agreement as a joint holder requiring such disclosure, Oasis does not intend to take any action triggering reporting obligations as a Joint Holder. The Document exclusively represents the opinions, interpretations, and estimates of Oasis. View source version on Contacts Media Contact For all inquiries, please contact:Taylor Hallmedia@
Yahoo
6 hours ago
- Yahoo
GRUPO SIMEC SAB DE CV ANNOUNCES THE PRESENTATION OF DOCUMENT 20F TO THE SEC
GUADALAJARA, Mexico, June 11, 2025 /PRNewswire/ -- Grupo Simec, S.A.B. de C.V. (NYSE-MKT: SIM) (the "Company") May 15, 2025 filed its Annual Report on Form 20-F for the year ended December 31, 2024 with the U.S. Securities and Exchange Commission at The Form 20-F is also available on the investor relations section of the Company's website at Shareholders may request a hard copy of the Form 20-F, including the Company's complete audited financial statements for the year ended December 31, 2024, free of charge, by contacting the Company's Finance coordinator, Mario Moreno Cortez, by email at mmoreno@ About Grupo Simec Grupo Simec is a diversified manufacturer, processor and distributor of SBQ steel and structural steel products with production and commercial operations in Mexico and Brazil, and limited commercial operations in the United States. Grupo Simec is also an important producer of structural and light structural steel products in Mexico in terms of sales volume. Grupo Simec's SBQ products are used across a broad range of highly engineered end-user applications, including axles, hubs and crankshafts for automobiles and light trucks, machine tools and off-highway. Contact: Mario Moreno CortezGrupo Simec, S.A.B. de Lázaro Cárdenas 60144440 Guadalajara, Jalisco, México+52 33 3770 6734 View original content: SOURCE Grupo Simec, S.A.B. de C.V.
